AI Terminal
Flerie AB
Net Asset Value • Jan 9, 2025
6601_rns_2025-01-09_174770ac-6e7d-4da8-a1f2-d82cff57c709.pdf
Net Asset Value
Open in ViewerOpens in native device viewer
NET ASSET VALUE – 31 December 2024
On the 31 December 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,198 million and NAV per share was SEK 53.77.
| Share of portfolio | Fair value | Part of NAV per share | Share of | |
|---|---|---|---|---|
| Allocation of NAV | company | (MSEK) | (SEK) | NAV |
| Product Development | ||||
| Prokarium | 42% | 486 | 6.23 | 11.6% |
| Xspray Pharma | 18% | 266 | 3.40 | 6.3% |
| KAHR Medical | 31% | 208 | 2.66 | 4.9% |
| Empros Pharma | 79% | 204 | 2.62 | 4.9% |
| Atrogi | 37% | 176 | 2.25 | 4.2% |
| Lipum | 57% | 141 | 1.80 | 3.4% |
| Microbiotica | 10% | 138 | 1.77 | 3.3% |
| Xintela | 61% | 131 | 1.68 | 3.1% |
| Geneos Therapeutics | 12% | 106 | 1.35 | 2.5% |
| Toleranzia | 66% | 103 | 1.32 | 2.4% |
| Mendus | 24% | 94 | 1.20 | 2.2% |
| AnaCardio | 17% | 69 | 0.89 | 1.7% |
| EpiEndo Pharmaceuticals | 9% | 57 | 0.73 | 1.4% |
| Synerkine Pharma | 43% | 53 | 0.68 | 1.3% |
| Egetis Therapeutics | 2% | 43 | 0.55 | 1.0% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.6% |
| Vitara Biomedical | 8% | 26 | 0.33 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 12 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,394 | 30.66 | 57.0% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.5% |
| Symcel | 31% | 174 | 2.23 | 4.1% |
| Provell Pharmaceuticals | 72% | 78 | 1.00 | 1.9% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| Nanologica | 43% | 70 | 0.89 | 1.7% |
| A3P Biomedical | 8% | 46 | 0.59 | 1.1% |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 665 | 8.52 | 15.8% | |
| Limited Partnerships, total | 91 | 1.16 | 2.2% |
| Net asset value | 4,198 | 53.77 | 100.0% |
|---|---|---|---|
| Other assets and liabilities | 855 | 10.96 | 20.4% |
| Assets related to Portfolio companies |
193 | 2.47 | 4.6% |
* indirect shares in Provell Pharmaceuticals
For more information:
Ted Fjällman, CEO Email: [email protected]
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com